SOPHIA ANTIPOLIS, France, October 22 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today reported financial results for the nine months ended September 30, 2008. Key highlights of the third quarter of 2008: - Positive top-line results from the 302 study for naproxcinod. The study met all three co-primary efficacy endpoints at week-13 (p